Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

National Cancer Registrars Association launches campaign to protect U.S. cancer registries

The National Cancer Registrars Association launched an advocacy campaign asking the public to contact their representatives and insist upon the protection of essential public health professionals and adequate funding of cancer prevention and research.

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a phase III clinical trial by researchers at City of Hope.

May 02, 2025

Vol.51 No.17

Podcast

In The Headlines: Are cancer registries on the chopping block, and what does it mean if they are?

The National Cancer Registries Program, or NPCR, is a relatively small but highly impactful 33-year-old CDC program that gauges disparities in cancer and tracks progress against the disease. So, why was it left out of the Trump administration’s preliminary budget?

April 30, 2025

Vol.51 No.16

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models.

April 25, 2025

Vol.51 No.16

By Claire Marie Porter

Cancer Policy

White House preliminary budget document provides no funds for highly impactful CDC cancer registries program

Over the past week, as cancer control experts scoured through a confidential budget document called the “passback” budget, they haven’t been able to find any trace of a relatively small but highly impactful program that funds state cancer registries.

ASCO seeks to engage new leaders of NIH, CMS, and FDA

The Association for Clinical Oncology has reached out to the new leaders of federal health agencies to ensure continued progress in cancer care, research, and patient access, the organization said.

April 25, 2025

Vol.51 No.16

By Jacquelyn Cobb

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

YOU MAY BE INTERESTED IN

National Cancer Registrars Association launches campaign to protect U.S. cancer registries

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

In The Headlines: Are cancer registries on the chopping block, and what does it mean if they are?

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

White House preliminary budget document provides no funds for highly impactful CDC cancer registries program

ASCO seeks to engage new leaders of NIH, CMS, and FDA

Renew today!

Subscriber content

Never miss an issue!

Login

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

YOU MAY BE INTERESTED IN

National Cancer Registrars Association launches campaign to protect U.S. cancer registries

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

In The Headlines: Are cancer registries on the chopping block, and what does it mean if they are?

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industryCommissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

White House preliminary budget document provides no funds for highly impactful CDC cancer registries program

ASCO seeks to engage new leaders of NIH, CMS, and FDA

Never miss an issue!

Login

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas